Spots Global Cancer Trial Database for incb018424
Every month we try and update this database with for incb018424 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Phase l/II Study of Ruxolitinib for Acute Leukemia | NCT01251965 | Leukemia | Ruxolitinib | 14 Years - | M.D. Anderson Cancer Center | |
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | NCT01243944 | Polycythemia Ve... | ruxolitinib tab... Best Available ... | 18 Years - | Incyte Corporation | |
Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT01895842 | Leukemia | Ruxolitinib | 18 Years - | M.D. Anderson Cancer Center | |
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | NCT01243944 | Polycythemia Ve... | ruxolitinib tab... Best Available ... | 18 Years - | Incyte Corporation | |
INCB018424 in Patients With Advanced Hematologic Malignancies | NCT00674479 | Acute Myeloid L... Acute Lymphocyt... Myelodysplastic... Chronic Myeloge... | INCB018424 | 18 Years - | M.D. Anderson Cancer Center | |
Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT01895842 | Leukemia | Ruxolitinib | 18 Years - | M.D. Anderson Cancer Center |